2nd International Conference on CRISPR Technologies

December 10-12, 2018

Presented by the Society for Biological Engineering (SBE), this conference will bring together leaders and trainees from the cutting edge of CRISPR technologies and their application to genome editing and beyond. Academic, clinical, and industrial researchers are invited to share their recent discoveries to progress the field in CRISPR science and engineering.

Technical Program

CRISPR technologies have been widely embraced for both basic and applied research. This space has rapidly moved forward since the first demonstration of Cas9-mediated genome editing with the discovery of new nucleases, the development of diverse and novel CRISPR applications for genome editing, gene regulation, in vitro applications, and the use of CRISPR technologies in diverse organisms, including, prokarynotes, plants, and animals.

CRISPR Conference Flyer

Keynote Speaker

Invited Speakers

Session Topics

  • CRISPR-Cas biology
  • Genome editing and DNA repair
  • Clinical applications of CRISPR
  • Beyond editing: novel applications
  • CRISPR-based gene drives
  • Delivery and specificity of CRISPR-based tools
  • Social, ethical, and economic implications of CRISPR-based technologies

Conference Chairs

Organizing Committee

Featured Speakers

Omar Akbari

In May of 2005, Omar S. Akbari received a B.S./M.S. in Biotechnology from the University of Nevada, Reno. In December of 2008, he received a Ph.D. in Cell and Molecular Biology from the University of Nevada, Reno where he studied the role cis-regulatory modules play in cellular identity along the anterio-posterior axis in developing Drosophila melanogaster embryos. In fall of 2017, he joined the faculty as an Assistant Professor in the Cell and Developmental Biology Section, within the Division of Biological Sciences, and a member of the TATA institute for Genetics and Society at the University of California, San Diego.Read more

Chase L. Beisel

Chase L. Beisel, PhD, is a group leader in the Helmholtz Institute for RNA-based Infection Research. Dr. Beisel received his BS in chemical engineering from Iowa State Univ. and his PhD in chemical engineering from the California Institute of Technology, and he held a postdoctoral fellowship in bacterial genetics at the National Institutes of Health (NIH). He then began his faculty career as an assistant professor in the department of chemical and biomolecular engineering at North Carolina State University. After being promoted to associate professor with tenure, Dr. Beisel transitioned to the Helmholtz Institute.Read more

Wei Leong Chew

Dr. Wei Leong Chew is GIS Fellow at the Genome Institute of Singapore, A*STAR. His lab develops technologies for making pinpoint changes in the human genome. His work contributed to the first demonstrations of postnatal disease gene correction and transcriptional activation with CRISPR-Cas9. He identified the immunogenic determinants on AAV-CRISPR-Cas9, providing a first insight into the safety profile of CRISPR therapeutics. He co-directs the Molecular Therapeutics Programme - the first DNA and RNA -targeting therapeutics development center in Southeast Asia. Dr. Chew graduated from Duke...Read more

Charles Gersbach

Dr. Charles A. Gersbach is the Rooney Family Associate Professor at Duke University in the Departments of Biomedical Engineering and Orthopaedic Surgery, an Investigator in the Duke Center for Genomic and Computational Biology, and Director of the Duke Center for Biomolecular and Tissue Engineering.Read more

Patrick Hsu

Patrick is a Principal Investigator and Salk Helmsley Fellow at the Salk Institute for Biological Studies. He received his B.A. from the University of California, Berkeley, as well as A.M. and Ph.D. degrees from Harvard University. Working with Feng Zhang and Xiaowei Zhuang at the Broad Institute of MIT and Harvard and the McGovern Institute for Brain Research at MIT, he contributed to the early development of CRISPR-Cas9 genome engineering technologies for efficient and precise application in eukaryotic cells.Read more

Yinan Kan

Yinan Kan is the Principle Scientist in the eGenesis gene editing team. He received his Ph.D. degree in 2015 in Biochemistry, Molecular Biology and Biophysics in the University of Minnesota with a research focus of dissecting the DNA repair pathways underlying homology-directed genome editing. He conducted postdoc research at Harvard Medical School before joining eGenesis Inc. He is devoted to developing novel technological platforms for multiplexed, precision and long-range genome editing with the aim of delivering safe and effective human transplantable organs from...Read more

Alexis Komor

Alexis Komor received her B. S. degree in chemistry from the University of California at Berkeley in December of 2008. While at Berkeley, she conducted research under the guidance of Professor Christopher J. Chang on the design of first-row transition metal catalysts for dioxygen activation and group transfer for three years. She then joined the lab of Jacqueline K. Barton at the California Institute of Technology for her doctoral studies. While at Caltech, she worked as an NSF Graduate Research Fellow on the design, synthesis, and study of DNA mismatch-binding metal complexes and received...Read more

Prashant Mali

Prashant Mali received a bachelor’s and master’s in Electrical Engineering from the Indian Institute of Technology Bombay, with a research focus on solid-state biosensors; and a doctorate in Biomedical Engineering at the Johns Hopkins University, with a research focus on human pluripotent stem cell engineering. During his postdoctoral fellowship in the Department of Genetics at the Harvard Medical School, he pioneered the development of the CRISPR-Cas systems for eukaryotic genome engineering. For his graduate work he received the Siebel Scholar Award in 2011, and in 2014 he...Read more

Megan Palmer

Dr. Megan J. Palmer is a Senior Research Scholar at the Center for International Security and Cooperation (CISAC) at Stanford University. She leads a research and practice program on risk governance in emerging technology development, with a focus on how security is conceived and managed as biotechnology becomes increasing accessible. Her current projects focus on assessing strategies for governing dual use research, analyzing the international diffusion of safety norms and practices, and the understanding the security implications of alternative technology design decisions.Read more

Shengdar Tsai

Dr. Tsai is an Assistant Member in the Department of Hematology at St. Jude Children’s Research Hospital. His lab currently focuses on genome editing technologies for therapeutics, with a special interest in potentially curative genome editing strategies for treatment of hemoglobinopathies such as sickle cell disease. Previously, he has developed methods for high-throughput genome editing with TALENs, and for defining and improving the genome-wide specificity of CRISPR-Cas nucleases. Dr. Tsai completed a postdoctoral fellowship at Massachusetts General Hospital & Harvard Medical School...Read more

Fyodor Urnov

Fyodor Urnov, Ph.D., is Deputy Director at the Altius Institute for Biomedical Sciences, where he shares broad responsibility for defining and leading the overall scientific effort. He is an author of more than 70 scientific publications and an inventor on more than 130 issued and pending U.S. patents related to genome editing and targeted gene regulation technology.Read more

Harris Wang

Harris Wang is an Assistant Professor at Columbia University jointly appointed in the Department of Systems Biology and the Department of Pathology and Cell Biology. Dr. Wang received his B.S. degrees in Mathematics and Physics from MIT and his Ph.D. in Biophysics from Harvard University.Read more

Yan Zhang

Yan Zhang is an Assistant Professor in the Department of Biological Chemistry at the University of Michigan Medical School. Her research group employs complementary biochemical, genetic, genomic, and microbiological approaches to study the non-canonical roles of Cas9 in RNA targeting and bacterial endogenous control, the mechanisms for adaptive CRISPR immunity, and to also develop novel CRISPR-based technological tools.Read more

John Zuris

John Zuris has long been drawn towards developing protein-based medicines and found a perfect home in the emerging CRISPR field. As a Scientist at Editas Medicine, he heads the Cpf1 group which focuses on using the CRISPR-Cpf1 modality for making better gene editing medicines. His group works at the exciting interfaces of protein design and cell therapy. Prior to joining Editas Medicine, John completed his postdoctoral training in the laboratory of Dr. David Liu (Harvard University-Broad Institute) where he developed a lipid nanoparticle delivery system for CRISPR-Cas9 RNPs which allows...Read more